Blau Farmaceutica SA
BOVESPA:BLAU3

Watchlist Manager
Blau Farmaceutica SA Logo
Blau Farmaceutica SA
BOVESPA:BLAU3
Watchlist
Price: 14.82 BRL -1.33%
Market Cap: 2.6B BRL
Have any thoughts about
Blau Farmaceutica SA?
Write Note

Intrinsic Value

The intrinsic value of one BLAU3 stock under the Base Case scenario is 23.42 BRL. Compared to the current market price of 14.82 BRL, Blau Farmaceutica SA is Undervalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BLAU3 Intrinsic Value
23.42 BRL
Undervaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Blau Farmaceutica SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BLAU3 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BLAU3?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Blau Farmaceutica SA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Blau Farmaceutica SA

Provide an overview of the primary business activities
of Blau Farmaceutica SA.

What unique competitive advantages
does Blau Farmaceutica SA hold over its rivals?

What risks and challenges
does Blau Farmaceutica SA face in the near future?

Summarize the latest earnings call
of Blau Farmaceutica SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Blau Farmaceutica SA.

Provide P/S
for Blau Farmaceutica SA.

Provide P/E
for Blau Farmaceutica SA.

Provide P/OCF
for Blau Farmaceutica SA.

Provide P/FCFE
for Blau Farmaceutica SA.

Provide P/B
for Blau Farmaceutica SA.

Provide EV/S
for Blau Farmaceutica SA.

Provide EV/GP
for Blau Farmaceutica SA.

Provide EV/EBITDA
for Blau Farmaceutica SA.

Provide EV/EBIT
for Blau Farmaceutica SA.

Provide EV/OCF
for Blau Farmaceutica SA.

Provide EV/FCFF
for Blau Farmaceutica SA.

Provide EV/IC
for Blau Farmaceutica SA.

Show me price targets
for Blau Farmaceutica SA made by professional analysts.

What are the Revenue projections
for Blau Farmaceutica SA?

How accurate were the past Revenue estimates
for Blau Farmaceutica SA?

What are the Net Income projections
for Blau Farmaceutica SA?

How accurate were the past Net Income estimates
for Blau Farmaceutica SA?

What are the EPS projections
for Blau Farmaceutica SA?

How accurate were the past EPS estimates
for Blau Farmaceutica SA?

What are the EBIT projections
for Blau Farmaceutica SA?

How accurate were the past EBIT estimates
for Blau Farmaceutica SA?

Compare the revenue forecasts
for Blau Farmaceutica SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Blau Farmaceutica SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Blau Farmaceutica SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Blau Farmaceutica SA compared to its peers.

Compare the P/E ratios
of Blau Farmaceutica SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Blau Farmaceutica SA with its peers.

Analyze the financial leverage
of Blau Farmaceutica SA compared to its main competitors.

Show all profitability ratios
for Blau Farmaceutica SA.

Provide ROE
for Blau Farmaceutica SA.

Provide ROA
for Blau Farmaceutica SA.

Provide ROIC
for Blau Farmaceutica SA.

Provide ROCE
for Blau Farmaceutica SA.

Provide Gross Margin
for Blau Farmaceutica SA.

Provide Operating Margin
for Blau Farmaceutica SA.

Provide Net Margin
for Blau Farmaceutica SA.

Provide FCF Margin
for Blau Farmaceutica SA.

Show all solvency ratios
for Blau Farmaceutica SA.

Provide D/E Ratio
for Blau Farmaceutica SA.

Provide D/A Ratio
for Blau Farmaceutica SA.

Provide Interest Coverage Ratio
for Blau Farmaceutica SA.

Provide Altman Z-Score Ratio
for Blau Farmaceutica SA.

Provide Quick Ratio
for Blau Farmaceutica SA.

Provide Current Ratio
for Blau Farmaceutica SA.

Provide Cash Ratio
for Blau Farmaceutica SA.

What is the historical Revenue growth
over the last 5 years for Blau Farmaceutica SA?

What is the historical Net Income growth
over the last 5 years for Blau Farmaceutica SA?

What is the current Free Cash Flow
of Blau Farmaceutica SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Blau Farmaceutica SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Blau Farmaceutica SA

Current Assets 1.6B
Cash & Short-Term Investments 431.9m
Receivables 601.9m
Other Current Assets 552.1m
Non-Current Assets 1.7B
Long-Term Investments 265.2m
PP&E 800.4m
Intangibles 447m
Other Non-Current Assets 143m
Current Liabilities 455.8m
Accounts Payable 219.5m
Accrued Liabilities 112.2m
Other Current Liabilities 124.1m
Non-Current Liabilities 688.5m
Long-Term Debt 483.5m
Other Non-Current Liabilities 205m
Efficiency

Earnings Waterfall
Blau Farmaceutica SA

Revenue
1.7B BRL
Cost of Revenue
-1.1B BRL
Gross Profit
596.5m BRL
Operating Expenses
-330.6m BRL
Operating Income
265.9m BRL
Other Expenses
-78.9m BRL
Net Income
187m BRL

Free Cash Flow Analysis
Blau Farmaceutica SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Blau achieved record revenue of BRL 465 million in Q2 '24, up from BRL 387 million in Q4 '23, driven by a resilient pharmaceutical market. Key initiatives included speeding up market entry across three business units and acquiring Bergamo, which boosted revenue and operational efficiency by 320 basis points. Continued investments in research and development were highlighted, with BRL 150 million invested over the last 12 months. The company’s organic revenue grew by 16%, while expanding into Retail, Aesthetics, and Plasma segments, leading to a 60% revenue increase in these areas.

What is Earnings Call?
Fundamental Scores

BLAU3 Profitability Score
Profitability Due Diligence

Blau Farmaceutica SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Operating Income
Positive 3-Year Average ROIC
Positive 3-Year Average ROE
58/100
Profitability
Score

Blau Farmaceutica SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

BLAU3 Solvency Score
Solvency Due Diligence

Blau Farmaceutica SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Positive Net Debt
57/100
Solvency
Score

Blau Farmaceutica SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BLAU3 Price Targets Summary
Blau Farmaceutica SA

Wall Street analysts forecast BLAU3 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BLAU3 is 18.14 BRL with a low forecast of 14.65 BRL and a high forecast of 23.63 BRL.

Lowest
Price Target
14.65 BRL
1% Downside
Average
Price Target
18.14 BRL
22% Upside
Highest
Price Target
23.63 BRL
59% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BLAU3?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BLAU3 is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Blau Farmaceutica SA Logo
Blau Farmaceutica SA

Country

Brazil

Industry

Biotechnology

Market Cap

2.6B BRL

Dividend Yield

2.46%

Description

Blau Farmacêutica SA engages in the manufacturing of pharmaceuticals. The company is headquartered in Cotia, Sao Paulo and currently employs 1,700 full-time employees. The company went IPO on 2021-04-19. The firm focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The firm operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.

Contact

SAO PAULO
Cotia
Rodovia Raposo Tavares, 2833 Km 30,5, Barro Branco
+551146159400
www.blau.com

IPO

2021-04-19

Employees

1 700

Officers

Founder, Controller, CEO & Deputy Chairman
Mr. Marcelo Rodolfo Hahn
CFO & Investor Relations Officer
Mr. Douglas Leandro Rodrigues
COO & Director
Mr. Roberto Carlos de Campos Morais
Legal & Compliance Officer
Mr. Roberto Altieri

See Also

Discover More
What is the Intrinsic Value of one BLAU3 stock?

The intrinsic value of one BLAU3 stock under the Base Case scenario is 23.42 BRL.

Is BLAU3 stock undervalued or overvalued?

Compared to the current market price of 14.82 BRL, Blau Farmaceutica SA is Undervalued by 37%.

Back to Top